Search | Clinical Trials Finder

Conditions: Transplant Rejection
Interventions: BIVV020 (SAR445088), Intravenous immunoglobulin (IVIg), Rituximab or biosimilar, Antithymocyte globulin (ATG), Tacrolimus, Mycophenolate, Corticosteroids; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • San Francisco, California • Boston, Massachusetts + 2 more

Conditions: Glioblastoma
Interventions: Trans Sodium Crocetinate plus SOC, Standard of Care (SOC); Drug · Other
Lead sponsor: Diffusion Pharmaceuticals Inc; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Irvine, California • Redwood City, California • Santa Monica, California + 10 more

Conditions: Alveolar Bone Loss
Interventions: INFUSE® Bone Graft; Device
Lead sponsor: Medtronic Spinal and Biologics; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Loma Linda, California • Los Angeles, California • Sarasota, Florida + 3 more

Conditions: Patellofemoral Pain Syndrome, Anterior Knee Pain Syndrome
Interventions: Blood Flow Restriction Cuff, Sham and standard of Care Therapy; Device · Procedure
Lead sponsor: Gaylord Hospital, Inc; Other
Eligibility: 15 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 6
States / cities: Cheshire, Connecticut • Cromwell, Connecticut • Farmington, Connecticut + 2 more

Conditions: Lupus Nephritis
Interventions: Ianalumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 1
States / cities: Orchard Park, New York

Conditions: Anti-Glomerular Basement Membrane Disease, Anti-Glomerular Basement Membrane Antibody Disease, Goodpasture Syndrome, Good Pasture Syndrome
Interventions: Imlifidase, Plasma exchange (PLEX), Cyclophosphamide (CYC), Glucocorticoids; Drug · Procedure
Lead sponsor: Hansa Biopharma AB; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more

Conditions: Inguinal Hernia
Interventions: Open Inguinal Hernia Repair, Laparoscopic Inguinal Hernia Repair, Robotic-Assisted Inguinal Hernia Repair; Procedure · Device
Lead sponsor: Intuitive Surgical; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Actinic Keratoses
Interventions: 5% 5-fluorouracil (5-FU) powder, 5% 5-fluorouracil (5-FU) powder PLUS 15% Aluminum Chloride Hexahydrate (ACH); Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Diabetic Foot Ulcer
Interventions: Standard of Care, PuraPly AM, PuraPly XT; Other · Device
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Clevland, Ohio

Conditions: Lymphoma, Non-Hodgkin
Interventions: Standard of Care, JCAR017; Drug · Genetic
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 28
States / cities: Scottsdale, Arizona • San Francisco, California • Aurora, Colorado + 22 more

Conditions: Postpartum, Hypertension, Hypertensive Disorder of Pregnancy
Interventions: 2-Week Home Monitoring, 6-Week Home Monitoring; Diagnostic Test
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Wound Chronic Draining, Wound Closure
Interventions: Platelet-rich fibrin (PRF); Device
Lead sponsor: Estar Medical dba Medical Technologies, LTD; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 3
States / cities: Bradenton, Florida • San Antonio, Texas

Conditions: Gait
Interventions: standard of care treatment, Ankle Flexion Dynasplint; Other · Device
Lead sponsor: Dynasplint Systems, Inc.; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 2
States / cities: Columbus, Ohio • Lubbock, Texas

Conditions: HIV Infections
Interventions: Standard of Care (SOC) Oral ART, Oral RPV, Oral CAB, RPV-LA Loading Dose, CAB-LA Loading Dose, RPV-LA Maintenance Dose, CAB-LA Maintenance Dose; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 32
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more

Conditions: Atopic Dermatitis
Interventions: Wrist Actigraphy Devices, Polysomnography, Videography; Device
Lead sponsor: Boston University; Other
Eligibility: 2 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cataract
Interventions: Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}, Ketorolac (0.5%) {Toradol}, moxifloxacin (0.5%) {VIGAMOX}, prednisolone acetate (1%) {Pred Forte}; Drug
Lead sponsor: Inder Paul Singh, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Venice, Florida • Racine, Wisconsin

Conditions: Kidney Transplantation
Interventions: CFZ533, Tacrolimus (Tac), Mycophenolate mofetil (MMF), Corticosteroids (CS), anti-IL2 Induction; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 6
States / cities: Aurora, Colorado • Baltimore, Maryland • Ann Arbor, Michigan + 3 more

Conditions: Non-Specific Chronic Lower Back Pain
Interventions: NexWave, Sham; Device
Lead sponsor: Zynex Medical, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Greenwood Village, Colorado • Saint Augustine, Florida • Atlanta, Georgia + 5 more

Conditions: Cancer
Interventions: Chaplain-Provided Spiritual Care, Psychotherapy and Meditation Intervention; Behavioral
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 854 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Colorectal Cancer
Interventions: Telisotuzumab Adizutecan, Standard of Care; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more

Conditions: Stimulant Abuse, HIV Prevention, Substance Abuse
Interventions: IMPACT, Standard of Care; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 205 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Miami, Florida • Boston, Massachusetts

Conditions: Asthma
Interventions: Placebo once daily, QAW039 150 mg once daily, QAW039 450 mg once daily; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 604 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Newport Beach, California • Westminster, California • Winter Park, Florida + 6 more

Conditions: Lung Cancer (Diagnosis)
Interventions: Standard medical treatment; Other
Lead sponsor: bioAffinity Technologies Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 2,063 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 11
States / cities: Palo Alto, California • Grand Junction, Colorado • Bay Pines, Florida + 7 more

Conditions: Infection
Interventions: Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Localized Alveolar Ridge Augmentation With Dental Implant

Clinical Comparison of Patellofemoral Pain Syndrome Outcomes After Blood Flow Restriction Therapy

Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)

A Study With Imlifidase in Anti-GBM Disease

Pain and Quality of Life After Inguinal Hernia Repair

Actinic Keratoses Treated With 5-fluorouracil Plus Aluminum

A Study to Evaluate the Efficacy of a Purified Native Type 1 Collagen Extracellular Matrix With Polyhexamethylene Biguanide Antimicrobial (PCMP) and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

HOPE-BP 2.0: Evaluating the Optimal Duration of Postpartum Remote Blood Pressure Monitoring

Using TropoCells(R) Autologous Platelet-Rich Fibrin (PRF) to Treat Chronic Non-Healing Wounds

Toe Walker Gait Trial

The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE

Scratch Behavior Under Standard of Care

Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC

CCFZ533X2201 - PoC Study in de Novo Renal Transplantation

Randomized Blinded Evaluation of the Effects of TENS and IFC Compared to a Sham Device and SOC in Patients With Non-Specific CLBP

Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

Integrated BA and HIV RR Counseling for MSM With Stimulant Abuse

Systemic Corticosteroids Avoidance Study in Severe Asthma Patients

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)